NOVARTIS

NOVARTIS logo
🇨🇭Switzerland
Ownership
Public, Private
Established
1996-01-01
Employees
76K
Market Cap
$242.6B
Website
https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis

Phase 4
Completed
Conditions
First Posted Date
2005-09-08
Last Posted Date
2008-02-15
Lead Sponsor
Novartis
Registration Number
NCT00150059
Locations
🇵🇭

This study is not being conducted in the United States, Investigative Site, Philippines

Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation

Phase 4
Completed
Conditions
First Posted Date
2005-09-08
Last Posted Date
2008-02-01
Lead Sponsor
Novartis
Target Recruit Count
250
Registration Number
NCT00149877
Locations
🇨🇭

Novartis, Basel, Switzerland

Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

Phase 4
Completed
Conditions
First Posted Date
2005-09-08
Last Posted Date
2008-01-24
Lead Sponsor
Novartis
Target Recruit Count
728
Registration Number
NCT00150020
Locations
🇺🇸

Novartis, East Hanover, New Jersey, United States

To Assess the Efficacy of Over-the-counter Analgesics in the Prevention/Treatment of Transient Post-dose Symptoms Following Zoledronate Infusion in Post-menopausal Women

Phase 3
Completed
Conditions
First Posted Date
2005-09-05
Last Posted Date
2012-04-27
Lead Sponsor
Novartis
Target Recruit Count
455
Registration Number
NCT00145275

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2005-09-05
Last Posted Date
2011-06-28
Lead Sponsor
Novartis
Target Recruit Count
2456
Registration Number
NCT00145327
Locations
🇺🇸

Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States

🇺🇸

Maine Center for Osteoporosis Research and Education, Bangor, Maine, United States

🇺🇸

Washington University Center for Clinical Studies, St. Louis, Missouri, United States

and more 27 locations

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Phase 2
Terminated
Conditions
First Posted Date
2005-09-02
Last Posted Date
2012-04-20
Lead Sponsor
Novartis
Target Recruit Count
120
Registration Number
NCT00142974
Locations
🇨🇭

Novartis, Basel, Switzerland

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Phase 4
Completed
Conditions
First Posted Date
2005-09-02
Last Posted Date
2017-03-29
Lead Sponsor
Novartis
Target Recruit Count
184
Registration Number
NCT00143026
Locations
🇨🇳

Kaohsiung Medical University, Chung-Ho Memorial Hospital, Linkou, Taiwan

🇹🇭

Pharmongkutklao Army Hospital, Bankok, Thailand

🇹🇭

King Chulalongkorn Memorial Hospital, Bangkok, Thailand

and more 15 locations

Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS

Phase 4
Completed
Conditions
First Posted Date
2005-09-02
Last Posted Date
2008-01-28
Lead Sponsor
Novartis
Target Recruit Count
664
Registration Number
NCT00142987

Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation.

Phase 3
Completed
Conditions
First Posted Date
2005-09-01
Last Posted Date
2008-02-01
Lead Sponsor
Novartis
Target Recruit Count
1026
Registration Number
NCT00141089
© Copyright 2024. All Rights Reserved by MedPath